GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » ROE % Adjusted to Book Value

AbCellera Biologics (STU:8QQ) ROE % Adjusted to Book Value : -16.30% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics ROE % Adjusted to Book Value?

AbCellera Biologics's ROE % for the quarter that ended in Dec. 2024 was -13.20%. AbCellera Biologics's PB Ratio for the quarter that ended in Dec. 2024 was 0.81. AbCellera Biologics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -16.30%.


AbCellera Biologics ROE % Adjusted to Book Value Historical Data

The historical data trend for AbCellera Biologics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics ROE % Adjusted to Book Value Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - 4.58 6.28 -8.28 -18.59

AbCellera Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.95 -12.08 -16.77 -25.90 -16.30

Competitive Comparison of AbCellera Biologics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, AbCellera Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's ROE % Adjusted to Book Value falls into.


;
;

AbCellera Biologics ROE % Adjusted to Book Value Calculation

AbCellera Biologics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-15.06% / 0.81
=-18.59%

AbCellera Biologics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-13.20% / 0.81
=-16.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Headlines

No Headlines